kidney disease
-
Novartis Lines Up $3.2B Deal for Kidney Disease Drugs, But FTC Questions Loom
Novartis is acquiring Chinook Therapeutics in a $3.2 billion deal that brings two late-stage drug candidates for a rare kidney disorder. The Novartis drug pipeline already has a molecule in late-stage development for the same kidney disease, which could raise questions from antitrust regulators.
-
Travere Therapeutics Drug for Rare Kidney Disease Falls Short in Pivotal Test
Sparsentan failed to meet the main goal of a Phase 3 test in focal segmental glomerulosclerosis (FSGS). Nevertheless, Travere Therapeutics says the totality of data points to patient improvement in the rare kidney disorder and the biotech will talk with regulators about a potential path forward.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Chinook Therapeutics Pauses Kidney Disease Drug Trial Following Adverse Event Report
The serious adverse event reported in the early-stage study resolved quickly, but Chinook Therapeutics said it is suspected to be related to its experimental primary hyperoxaluria therapy. Meanwhile, Human Immunology Biosciences is looking ahead to Phase 3 after its rare kidney disease drug posted positive mid-stage data.
-
FDA Approval of Travere Kidney Disease Drug Sets Up Blockbuster Expectations
Travere Therapeutics drug Filspari won accelerated FDA approval to treat a rare disorder that can lead to kidney failure. The small molecule is also in late-stage testing for another rare kidney disease; analysts say each indication represents a blockbuster opportunity.
-
Vera’s Drug for Rare Kidney Disease Hits Trial Goals. Can It Stand Out in the Field?
Atacicept, a Vera Therapeutics drug in development for the rare kidney disease immunoglobulin A nephropathy, is on its way to a pivotal test after achieving the main goal of a mid-stage clinical trial. But the results still fall short of data recently reported by a competitor that is addressing the same disease target.
-
Autoimmune Drug Biotech HI-Bio Unveils $120M to Root Out Cellular Drivers of Disease
Human Immunology Biosciences aims to stand apart in autoimmune disease drug research with therapies that address cells at the root of a range of allergic and inflammatory disorders. The biotech has a lead program licensed from MorphoSys in clinical development for two rare kidney diseases and $120 million to support that antibody and other biologic drugs in its pipeline.
-
Roche pays $55M for late-stage drug for rare kidney disease with no approved treatment
An Ionis Pharmaceuticals drug has positive Phase 2 results in immunoglobulin A nephropathy, leading Roche to exercise its option to license the rights to the molecule. The pharmaceutical giant gets a contender in the chase to win the first regulatory approval of a therapy for this rare kidney disease.
-
CSL shakes off pandemic woes, diversifies with $11.7B Vifor Pharma acquisition
CSL Limited makes many of its therapies from donated plasma, which posed a challenge as pandemic lockdowns led to a steep drop in plasma collections. In acquiring Vifor Pharma, CSL not only diversifies, it also expands its presence in the fast-growing nephrology market.
-
Startups, Health Services, Health Tech, Payers
Insurers back kidney care startup Cricket in $83.5M round
Cigna Ventures and Blue Shield of California contributed to a funding round for Cricket Health, a startup that provides services to help patients identify chronic kidney disease and get support in treatment. The investment was led by Valtruis, a firm that invests in value-based care companies.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Wall Street is lukewarm to Vera’s pivot from gene editing to rare kidney disease
Vera Therapeutics raised $47.9 million from its IPO to continue clinical development of its lead asset, a potential treatment for the kidney disease IgA nephropathy. But the company is joining a crowded field of companies aiming to develop a drug for the rare disorder.
-
Startups, Devices & Diagnostics, Diagnostics
Healthy.io raises $18M to bring smartphone urinalysis tech to U.S.
Healthy.io’s urinalysis testing kit – dubbed Dip.io – uses disposable strips and cups in conjunction with a smartphone camera to read and interpret results.
-
Renalytix AI raises $29M through IPO for AI-based kidney disease diagnostics
The company’s first product, a diagnostic aid known as KidneyIntelX is aiming to identify patients at risk for particularly fast progression of kidney disease.
-
Cricket Health locks in $24M to expand its footprint in the kidney care space
The startup, which leverages technology to assist chronic kidney disease and end-stage renal disease patients, has wrapped up a $24 million Series A round led by Oak HC/FT.
-
Third Rock invests $55M in ‘kidney renaissance’ startup
Third Rock Ventures has incubated, funded and launched another startup, Goldfinch Bio, committing $55M to its mission to modernize the treatment of kidney disease.
-
Cook Medical launches awareness campaign for World Kidney Day
Today is World Kidney Day, and Bloomington, Indiana-based medical device company Cook Medical is bringing awareness to chronic kidney disease (CKD) with a new campaign.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
